Navigation Links
BioWa Announces License of POTELLIGENT® Technology to Agensys
Date:11/15/2010

PRINCETON, N.J., Nov. 15, 2010 /PRNewswire/ -- BioWa, Inc. announced today that it has entered into a license agreement with Agensys, Inc., an affiliate of Tokyo based Astellas Pharma Inc., providing Agensys with access to BioWa's POTELLIGENT® Technology platform for the purpose of identifying antibodies with enhanced antibody-dependent cellular cytotoxicity (ADCC).

"We are extremely pleased about our Agreement with Agensys, a leading monoclonal antibody organization with a focus on therapies against solid tumors," commented Dr. Masamichi Koike, BioWa's President and CEO. "Agensys world-class R&D organization and breath of targets in solid tumors will greatly extend the benefits of the POTELLIGENT® Technology."

Under the terms of the license agreement, BioWa grants Agensys non-exclusive rights to conduct research activities using POTELLIGENT® Technology for an undisclosed number of targets. In return, BioWa will receive annual research license fees. Other details of the agreement are not disclosed.

About POTELLIGENT® Technology

POTELLIGENT® Technology improves potency and efficacy of antibody therapeutics, by enhancing ADCC, one of the major mechanisms of action for antibody therapeutics. POTELLIGENT® Technology involves the reduction of the amount of fucose in the carbohydrate structure of an antibody using a proprietary fucosyltransferase-knockout Chinese Hamster Ovary (CHO) cell line as a production cell. Research shows that POTELLIGENT® Technology dramatically enhances ADCC activity of an antibody in vitro, and significantly increases potency and efficacy of the antibody in vivo. A number of POTELLIGENT® antibodies are being investigated in human clinical trials.

About BioWa, Inc.

BioWa is a wholly owned subsidiary of Kyowa Hakko Kirin Co., Ltd., Japan's leading pharmaceut
'/>"/>

SOURCE BioWa, Inc.
Copyright©2010 PR Newswire.
All rights reserved

Page: 1 2

Related medicine technology :

1. BioWa Announces Second Japanese License of POTELLIGENT(R) Technology to Otsuka Pharmaceutical
2. Dendreon Announces Publication of Phase 1 Study Highlighting Immunologic and Clinical Activity of Lapuleucel-T (Neuvenge(R)) in Advanced Breast Cancer Patients
3. EDAP Announces Launch of Clinical Study Combining HIFU and Chemotherapy for Localized Aggressive High Risk Prostate Cancer
4. Cephalon Announces Positive Results from a Pivotal Study of FENTORA in Opioid-tolerant Patients with Non-cancer Breakthrough Pain
5. ADVENTRX Announces Fast Track Designation Granted By the FDA For CoFactor For the Treatment of Metastatic Colorectal Cancer
6. DOV Pharmaceutical, Inc. Announces Successful Phase Ib Results for DOV 21,947
7. Phosphagenics Announces Positive Phase 1b Transdermal Insulin Clinical Trial Results
8. Xenomics Announces Implementation of its First Diagnostic Test for Acute Myeloid Leukemia Into Clinical Practice
9. Emisphere Technologies, Inc. Announces 2007 Second Quarter Financial Results
10. Amicus Therapeutics Announces Second Quarter 2007 Financial Results
11. Genta Incorporated Announces Second Quarter 2007 Financial Results and Corporate Highlights
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:1/15/2014)... Jan. 15, 2014 Tegra Medical is very pleased to ... as its new Chief Executive Officer.  Mark was promoted from ... has overseen the company,s four facilities in Massachusetts ... Mr. King joined Tegra Medical in 2012 with 20+ years ...
(Date:1/15/2014)... TORONTO , Jan. 15, 2014  According to ... medical technology market intelligence, the United ... occlusion (TEO) device markets will expand moderately through ... fastest-growing segments. In particular, increasing interest in drug-eluting ...
(Date:1/15/2014)... , Jan. 15, 2014 Reportlinker.com ... is available in its catalogue: ... Advanced Drug Delivery Systems -- Focus on ... STUDY OBJECTIVES A ...
Breaking Medicine Technology:Tegra Medical Appoints New Chief Executive Officer 2Tegra Medical Appoints New Chief Executive Officer 3US and European Transcatheter Embolization and Occlusion Device Market to Surpass $1.6 Billion by 2022 2US and European Transcatheter Embolization and Occlusion Device Market to Surpass $1.6 Billion by 2022 3Global Markets and Technologies for Advanced Drug Delivery Systems -- Focus on End Users 2Global Markets and Technologies for Advanced Drug Delivery Systems -- Focus on End Users 3Global Markets and Technologies for Advanced Drug Delivery Systems -- Focus on End Users 4Global Markets and Technologies for Advanced Drug Delivery Systems -- Focus on End Users 5Global Markets and Technologies for Advanced Drug Delivery Systems -- Focus on End Users 6Global Markets and Technologies for Advanced Drug Delivery Systems -- Focus on End Users 7Global Markets and Technologies for Advanced Drug Delivery Systems -- Focus on End Users 8Global Markets and Technologies for Advanced Drug Delivery Systems -- Focus on End Users 9Global Markets and Technologies for Advanced Drug Delivery Systems -- Focus on End Users 10Global Markets and Technologies for Advanced Drug Delivery Systems -- Focus on End Users 11Global Markets and Technologies for Advanced Drug Delivery Systems -- Focus on End Users 12Global Markets and Technologies for Advanced Drug Delivery Systems -- Focus on End Users 13Global Markets and Technologies for Advanced Drug Delivery Systems -- Focus on End Users 14Global Markets and Technologies for Advanced Drug Delivery Systems -- Focus on End Users 15Global Markets and Technologies for Advanced Drug Delivery Systems -- Focus on End Users 16Global Markets and Technologies for Advanced Drug Delivery Systems -- Focus on End Users 17Global Markets and Technologies for Advanced Drug Delivery Systems -- Focus on End Users 18
... 25, 2011 PDI, Inc. (Nasdaq: ... and commercialization services to health care companies, today announced ... 10 pharmaceutical company has been renewed for an additional ... Shared Sales team beginning in September 2011 through March ...
... 2011 Adeona Pharmaceuticals, Inc. (NYSE Amex: AEN ) ... who has conducted multiple clinical studies of zinc lozenges for the ... Mr. Eby is a pioneer in the development of zinc ... more than 30 years to the study of zinc and is ...
Cached Medicine Technology:PDI Announces Renewal of Engagement for 7th Consecutive Season 2Adeona Appoints George A. Eby to Scientific Advisory Board 2Adeona Appoints George A. Eby to Scientific Advisory Board 3Adeona Appoints George A. Eby to Scientific Advisory Board 4
(Date:4/17/2014)... April issue of Experimental Biology and Medicine ... Rex Gaskins and Paul Kenis in the Institute ... the University of Illinois Urbana-Champaign describe their recent ... underlie a variety of cell functions including energy ... crucial roles in regulating normal cellular behavior, redox ...
(Date:4/17/2014)... 2014) Two recent papers by a University ... may help scientists develop treatments or vaccines for ... encephalitis and other disease-causing flaviviruses. , Jeffrey S. ... genetics at the School of Medicine and an ... Institute, and colleagues recently published articles in the ...
(Date:4/17/2014)... Pediatrician-in-Chief Jon McCullers, MD, was recently invited to ... Nature Reviews Microbiology , one of the ... world-renowned infectious disease specialist, and chair of the ... Health Science Center, analyzed the epidemiology and microbiology ... pandemics, as well as more recent 2009 novel ...
(Date:4/17/2014)... April 17, 2014U.S. military personnel who served in ... concussive traumatic brain injury (TBI) were compared to ... other medical reasons. Differences in measures of overall ... months after injury are reported in an article ... journal from Mary Ann Liebert, Inc., publishers. The ...
(Date:4/17/2014)... older Americans suffer from depression, often brought on by ... a project that followed the lives of thousands ... that Internet use among the elderly can reduce the ... "That,s a very strong effect," said Shelia Cotten, a ... media who led the project. "And it all has ...
Breaking Medicine News(10 mins):Health News:Live cell imaging reveals distinct alterations of subcellular glutathione potentials 2Health News:CU researchers discover target for treating dengue fever 2Health News:Long-term effects of battle-related 'blast plus impact' concussive TBI in US military 2Health News:Internet use can help ward off depression among elderly 2
... shoot out, the government of Nepal paid compensation of Nepali Rs. ... was shot dead in Kathmandu valley Monday during a shutdown called ... ,The government also paid around Nepali Rs.150,000 to the ... in the polls. ,However, when one looks at the ...
... Taking the cue from the level of nutrition awareness in people ... calorie content on the front of their packets//. This is ... ,The majorFood companies in the health race are Danone, ... Food Standards Agency's (FSA) proposed 'traffic light' labels in favour ...
... Public health care system, with fear amongst people of ... ripples amongst people. The decade old system surely needs dissection, ... healthcare.// ,Canada health care is notorious for prolonged ... even explore the option of availing other countries’ health care ...
... Toronto: Health officials have flashed a warning to be on ... cases reported spreads through Toronto. ,Since November, nearly 167 ... public health department, called as a whooping cough with under ... are vaccinated against the disease, the vaccine is not known ...
... unrealistic standards of beauty are most commonly blamed for ... on this trend, // a lot of marketing companies ... to convey messages in an effective way. ... women are more likely to lower the onlooker’s self ...
... Hyperactivity Disorder (ADHD), Ritalin (Novartis AG) and Adderall (Shire ... assess the safety and side effects // of the ... the reports of the U.S. advisory panel, which stated ... such drugs. There is a possibility of sudden death, ...
Cached Medicine News:
Engineered for high volume surgical efficiencies, the Bausch & Lomb Hansatome Microkeratome, a corneal resection instrument, features an automated pivoting motion that provides smooth, resistance-fre...
... provide comprehensive neurological monitoring in the ... to accurately access your patients neurological ... years experience, and a long history ... monitoring systems have a proven record ...
... Alpha 5 is Aloka's latest advance ... operating room. Aloka's ProSound technology transmits ... information in a pure sound field., ... large-scale integration of the electronic circuit ...
Inquire...
Medicine Products: